Document Detail

Schiff plus click: one-pot preparation of triazole-substituted iminopyridines and ring opening of the triazole ring.
MedLine Citation:
PMID:  23212625     Owner:  NLM     Status:  Publisher    
The use of Schiff condensation followed by CuAAC affords complexes containing iminopyridine ligands functionalized either with a triazole ring or with a sulfonyl amido group via ring opening of the unstable sulfonyl triazole.
Celedonio M Alvarez; Luis A García-Escudero; Raúl García-Rodríguez; Daniel Miguel
Related Documents :
18816555 - Stannylated polynorbornenes as new reagents for a clean stille reaction.
24098235 - (3ar,6s,7ar)-7a-chloro-2-[(4-nitro-phen-yl)sulfon-yl]-1,2,3,6,7,7a-hexa-hydro-3a,6-ep-o...
18590295 - Metallization of a thiol-terminated organic surface using chemical vapor deposition.
20683535 - The first unpaired electron placed inside a c3-symmetry p-chirogenic cluster.
24315445 - Mononuclear anionic octahedral cobalt(iii) complexes based on n-salicylidene-o-aminophe...
19673505 - Bis(oxazolinylmethyl)pyrrole derivatives and their coordination as chiral "pincer" liga...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-5
Journal Detail:
Title:  Dalton transactions (Cambridge, England : 2003)     Volume:  -     ISSN:  1477-9234     ISO Abbreviation:  Dalton Trans     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101176026     Medline TA:  Dalton Trans     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
GIR-MIOMeT-IU CINQUIMA/Química Inorgánica, Facultad de Ciencias, Universidad de Valladolid, Valladolid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Fractional laser-assisted delivery of methyl aminolevulinate: Impact of laser channel depth and incu...
Next Document:  Recent updates on the development of ganetespib as a Hsp90 inhibitor.